

UC San Diego

UC San Diego Previously Published Works

Title

Integrated Metabolomic-Genomic Workflows Accelerate Microbial Natural Product Discovery

Permalink

<https://escholarship.org/uc/item/5vw7k64q>

Journal

Analytical Chemistry, 94(35)

ISSN

0003-2700

Authors

Avalon, Nicole E
Murray, Alison E
Baker, Bill J

Publication Date

2022-09-06

DOI

10.1021/acs.analchem.2c02245

Peer reviewed

Integrated Metabolomic–Genomic Workflows Accelerate Microbial Natural Product Discovery

Nicole E. Avalon,* Alison E. Murray,* and Bill J. Baker*

Cite This: *Anal. Chem.* 2022, 94, 11959–11966


Read Online

ACCESS |

Metrics & More

Article Recommendations

ABSTRACT: The pairing of analytical chemistry with genomic techniques represents a new wave in natural product chemistry. With an increase in the availability of sequencing and assembly of microbial genomes, interrogation into the biosynthetic capability of producers with valuable secondary metabolites is possible. However, without the development of robust, accessible, and medium to high throughput tools, the bottleneck in pairing metabolic potential and compound isolation will continue. Several innovative approaches have proven useful in the nascent stages of microbial genome-informed drug discovery. Here, we consider a number of these approaches which have led to prioritization of strain targets and have mitigated rediscovery rates. Likewise, we discuss integration of principles of comparative evolutionary studies and retrobiosynthetic predictions to better understand biosynthetic mechanistic details and link genome sequence to structure. Lastly, we discuss advances in engineering, chemistry, and molecular networking and other computational approaches that are accelerating progress in the field of omic-informed natural product drug discovery. Together, these strategies enhance the synergy between cutting edge omics, chemical characterization, and computational technologies that pitch the discovery of natural products with pharmaceutical and other potential applications to the crest of the wave where progress is ripe for rapid advances.



Genomic approaches to drug discovery have not only focused on the study of human genomes to better understand protein targets, cellular cascades, drug resistance, epigenetics, and their implications on human disease to further refine drug discovery efforts,^{1,2} but genomic studies have revealed a vast repertoire of diversity in microbial metabolic innovation which can also be paired with metabolomics for the study of microbially produced secondary metabolites. Secondary metabolites have garnered great interest as potential pharmaceuticals as the diverse chemical scaffolds are well suited for biological targets.³ Over 50% of FDA-approved medications have been sourced directly from or inspired by nature.⁴

Historically, methods of natural product isolation and characterization relied heavily on extraction of secondary metabolites from both microorganisms and macroorganisms requiring time-intensive analytical procedures for isolation and compound characterization. Over time, several barriers to natural product discovery have been identified, such as high rediscovery rates and the potential ecological impact of mass field collections, with implications on the sustainability of the source. Technological advances have now ameliorated most of these concerns. For example, omics techniques have been harnessed to prioritize samples, quickly identify metabolites of interest, and utilize genomic information to inform natural product discovery.^{5–7} Technological advances also enhance the potential for a more sustainable exploration of nature's chemical


wealth and for creation of an ongoing supply of compounds through biotechnology.

One of the primary ways that genomics is integrated with drug discovery of natural products is by the identification of biosynthetic gene clusters (BGCs). BGCs encode for the enzymatic machinery, ranging in organization from single iteratively acting enzymes to multidomain megaenzymes with numerous catalytic sites, that are responsible for the biosynthesis of secondary metabolites.⁸ These discrete genomic elements are similar to, but evolutionarily divergent from, genes involved in primary metabolism (i.e., polyketide synthases are likely derived from fatty acid synthases). The genes have been evolutionarily repurposed to produce an array of architecturally diverse compounds under tight stereochemical controls with a strong affinity toward biological targets. BGCs can be horizontally transferred from one organism to another, a phenomenon that can be identified through phylogenetic analysis, as the evolutionary history of clustered elements within a BGC can be quite divergent from the remainder of the genome.^{9,10}

Received: May 25, 2022

Accepted: August 12, 2022

Published: August 22, 2022



Today, there is a wealth of publicly accessible databases tailored to the fields of genomics and natural products, some linking the two disciplines, and several of which are community-curated with ongoing contributions that serve as data resources (Table 1). Data sourced from these repositories are often used in

Table 1. List of Resources and Accompanying Website for Each of the Approaches Presented

Data resource	Website
Approach 1: Dereplication at the genomic level	
NCBI	https://www.ncbi.nlm.nih.gov/
BLAST	https://blast.ncbi.nlm.nih.gov
AntiSMASH	https://antismash.secondarymetabolites.org
AntiSMASH-DB	https://antismashdb.secondarymetabolites.org
IMG/ABC	https://img.jgi.doe.gov/cgi-bin/abc/main.cgi
MIBiG	https://mibig.secondarymetabolites.org
Approach 2: Prioritization based on microbial taxonomy	
BiG-SCAPE	https://bigscape-corason.secondarymetabolites.org
CORASON	https://github.com/nselem/corason/wiki
NaPDoS	https://npdomainseeker.sdsc.edu
AutoMLST	https://automlst.ziemertlab.com
Approach 3: Coevolutionary principles to guide discovery	
ARTS	https://arts.ziemertlab.com
EvoMining	https://github.com/nselem/EvoMining/wiki
CO-ED	http://enzyme-analysis.org
Approach 4: Retrobiosynthesis to target biosynthetic gene clusters	
Approach 5: Molecular networking to identify analogues	
GNPS	https://gnps.ucsd.edu
Approach 6: Pairing enzymatic domains with key structural features	
IsoAnalyst	https://github.com/liningtonlab/isoanalyst
Approach 7: Paired genome-metabolite databases for discovery	
NRPminer	https://github.com/mohimanilab/NRPminer
PoDP	https://pairedomicsdata.bioinformatics.nl
MetaMiner	https://github.com/mohimanilab/MetaMiner

comparative analyses with a multitude of software tools resulting in powerful analyses that are becoming more integrated due to improvements in cross-communication between the fields and resources available (Table 1). There were significant barriers in the past with databases having little crosstalk, particularly between different disciplines and technologies (e.g., biosynthetic gene cluster data with metabolomic profiles). This divide demonstrates the importance of interdisciplinary collaborations and community curation in natural product chemistry and is consistent with the movement toward open-source software that evolves and incorporates new tools and strategies.

The power of analytical chemistry in natural product drug discovery remains a critical element of the field. Traditional methods for isolation and characterization of natural products, notably the use of chromatography, mass spectrometry (MS), and nuclear magnetic resonance (NMR), are a mainstay for structure isolation and characterization. When combined with genome and metagenome-informed approaches, analytical techniques are being used to advance the technological frontier of drug discovery. Examples of these approaches are discussed below, and new approaches are proposed that will continue to merge the fields of genomics and metabolomics in a synergistic way to enhance natural product discovery efforts.

CONTEXT AND SCOPE: INTEGRATION OF INTERDISCIPLINARY OMICS APPROACHES TO ADVANCE NATURAL PRODUCT DISCOVERY EFFORTS

In this perspective, we explore emerging technologies and computational tools that pair genomic and metabolomic data for natural product drug discovery (Figure 1). What follows is a compilation of approaches (or workflows; Table 1) that highlight the synergy between genomics and analytical chemistry which will likely continue to enhance and refine microbial natural product discovery efforts. This is not meant to serve as a comprehensive overview of all available tools and strategies as there are several reviews that discuss mass spectral databases and genomic databases as well as tools aimed at mining the big data resulting from both. We refer the reader to those reviews for further information on the tools discussed here.^{5–7,11–13} The tools discussed here were published before January 2022.

WORKFLOWS FOR INTEGRATED APPROACHES TO GENOME-ENABLED NATURAL PRODUCT BIODISCOVERY

Approach 1: Dereplication at the Genomic Level to Reduce Rediscovery Rates of Known Natural Products and Enhance Discovery of Novel Natural Products. Dereplication of chemical structures, through detailed comparison of NMR and MS data of an isolated compound to the scientific literature and to chemical databases, is a long-standing strategy to reduce rediscovery in the early phases of natural product isolation process. A similar strategy can be employed for rapid dereplication using genomic information. BGCs identified in new (meta)genome sequences can be rapidly searched against global databases (e.g., NCBI)¹⁴ in addition to more curated tools (e.g., AntiSMASH)¹⁵ which assess homology across modules, genes, and full length BGCs. Due to the exponentially increasing volume of data, number of data repositories, and bioinformatic tools for known BGCs, we are in a renaissance of natural product biodiscovery.

Basic Local Alignment Search Tool (BLAST)¹⁶ searches have been a bioinformatic mainstay for comparing nucleotide and protein sequence information through the detection of regions of similarity between the inquiry sequence and a vast database of biological sequences with a broad range of taxonomic representation. There are innate limitations to BLAST searches for BGCs, however, given the lengthy multidomain nature of these cassettes. BLAST searches can help one gain a clearer understanding of the biosynthetic substructures; however, the tool is not well suited for rapid identification or comparison of entire BGCs or for unique and novel sequences.

The antiSMASH BGC annotation pipeline¹⁵ harbors annotations of putative BGCs based on their identifications using the antiSMASH algorithm. With over 150,000 putative BGCs, the ClusterBlast algorithm nested within antiSMASH compares submitted sequences to those in the database for analyses of fungal and bacterial BGCs.¹⁵ The Integrated Microbial Genome Atlas of Biosynthetic Gene Clusters (IMG/ABC)¹⁷ contains over 400,000 BGCs. Further, gene cluster families, which share similarities in gene structure, can be identified and visualized using BiGSCAPE.¹⁸ In concert, these integrated tools allow for rapid dereplication of genome-encoded BGC sequences that are critical in the biosynthesis of




Figure 1. Workflows for integration of genomic and metabolomic strategies for natural product discovery.

natural products and enhance the likelihood of discovery of not only new BGCs but also new secondary metabolites.

Recently, the scientific community has developed a common language and data standard to communicate the biosynthetic gene cluster data and associated chemistry. The standard, led by Kautsar and colleagues and referred to as the Minimum Information about a Biosynthetic Gene Cluster (MIBiG),¹⁹ is accompanied by a repository which houses nearly 2000 BGCs as of early 2022 (Figure 2). This resource allows for manual curation and annotation by the natural product community and the MIBiG developers. It serves as a centralized space to deposit and access valuable data about BGCs including information on enzymatic features, protein sequences, taxonomic origins, and associated chemical structures. MIBiG has also been incorporated into antiSMASH¹⁵ and is used to screen (meta)genomes

submitted for BGC analysis for similarity to known BGCs in the MIBiG database. Beyond identification of identical BGCs and dereplication, the referencing of the MIBiG repository within antiSMASH provides a percent identity score for submitted BGCs affording the opportunity to utilize the similarities in gene structure to target novel metabolites. On the basis of the differences in the gene sequence, differences in chemical structure can be inferred. This allows for rapid dereplication as part of the antiSMASH genome mining pipeline. Metagenomic libraries can therefore be efficiently interrogated for the presence of BGCs and evaluated for homologies to known BGCs. This strategy can guide prioritization of BGCs of interest for further investigation with cultivation or biotechnological measures.

Approach 2: Prioritization of Drug Discovery Efforts Based on Biosynthetic Potential of Certain Microbial Taxa. Across the immense diversity of the bacterial domain of life, the distribution of biosynthetic gene clusters is only recently becoming understood.²³ Certain bacterial taxonomic families are known to be more biosynthetically talented than others. However, biosynthetic potential, the likelihood that secondary metabolites can be produced, is understudied in many lineages. This makes the prospect for novelty high, particularly in poorly studied lineages, many of which have evaded cultivation. BGCs with low levels of similarity, in particular, those associated with poorly known phylogenetic uniqueness, can be used to mine novel BGCs and point to new compounds. Alternatively, novelty remains to be discovered even in more familiar lineages including two distinct bacterial groups that are known to be particularly rich in BGCs and known to produce bioactive compounds (filamentous cyanobacteria and *Streptomyces*). For example, Leão and colleagues characterized the biosynthetic potential based on BGC classes and resultant metabolites from tropical filamentous marine cyanobacteria.²⁴ They suggested that “natural product diversity hotspots” should be prioritized,




Figure 2. Nearly 500,000 BGCs have been identified, of which 87,000 are derived from metagenome-assembled genomes (MAGs). Of the identified natural products, only 2000 have been paired with BGCs, and only five of those are associated with metagenome-assembled genomes. Data obtained from NP Atlas,²⁰ IMG-ABC,²¹ MiBiG,¹⁹ and the GEM Catalog.²²

while ecosystems or niches with low beta-diversity when paired with low numbers of BGCs were deemed to be more likely to result in rediscovery of known natural products.²⁴ Many of the FDA-approved anti-infectives are derived from actinomycetes, specifically *Streptomyces* spp. There are several examples applying *Streptomyces*-targeted investigation that are yielding novelty. Soldatou and colleagues specifically looked at the biosynthetic potential residing within Arctic and Antarctic actinomycetes and, through extensive cultivation efforts and the one strain—many compounds (OSMAC) method, were able to confirm high rates of both metabolic diversity and anti-infective bioactivity.²⁵ The microbial diversity in Indonesian bacterial strains used a similar strategy of linking genomic and metabolomic data to leverage biosynthetic talent within their collection of *Streptomyces* spp. and promote the discovery of novel natural products.²⁶ Each of these research teams utilized the Biosynthetic Gene Similarity Clustering and Prospecting engine (BiG-SCAPE)¹⁸ which groups BGCs into gene cluster families based on sequence similarity networks. This software tool is now paired with the CORE Analysis of Syntenic Orthologues to prioritize Natural Product Gene Clusters (CORASON),¹⁸ a tool that defines phylogenetic relationships within gene cluster families.

Additional tools for rapid evaluation of biosynthetic potential based on phylogeny and taxonomy include NaPDos and AutoMLST. The Natural Product Domain Seeker (NaPDos) can be used to identify biosynthetic enzymes and therefore biosynthetic wealth, with a focus on PKS and NRPS genes, in genomic and metagenomic data.²⁷ This tool phylogenetically classifies condensation domains and ketosynthase domains resulting in a phylogenetic tree of these domains with those of known BGCs to help determine similarities with known biosynthetic pathways. Another phylogenetic tool that can aid in determining biosynthetic potential is the Automated Multi-Locus Species Tree (AutoMLST)²⁸ which builds phylogenetic trees from a simplified user interface to infer relationships of bacteria from the users' collections. The output includes taxonomic clade information, and data points can then be used to make inferences about the biosynthetic potential of the associated species.

For laboratory groups with extensive bacterial culture collections, prioritization of strains based on their phylogenetic placement can be key in streamlining drug discovery efforts. These strategies of prioritization can be paired with targeted large-scale cultivation efforts and subsequent natural product isolation and characterization as well as biotechnological means to express specific BGCs for drug discovery.

Approach 3: Use of Coevolutionary Principles to Guide Genome-Mining. Another valuable approach has been introduced by Ziemert and colleagues through the Antibiotic Resistant Target Seeker (ARTS).²⁹ The software tool pairs algorithms to determine phylogenetic discrepancies which may indicate horizontal gene transfer, with additional features such as gene duplication and proximity to resistance markers that can be used to highlight those clusters that may have an increased likelihood of producing anti-infective bioactive molecules.²⁹ Although the initial version was focused primarily on actinobacterial genomes, the release of the second ARTS version in 2020 expanded the tool to allow for analysis of genomes from all bacterial taxa as well as from metagenomic data. Since bacteria have been found to harbor resistance genes integral to the prevention of self-toxicity in genomic proximity to the secondary metabolites they produce,³⁰ this strategy is a way

to streamline genomic-based antibiotic discovery. These mechanisms include, but are not limited to, pro-drug formation, other chemical modification, use of efflux pumps, and self-resistant protein variants.³⁰ Manual interrogation for specific markers not yet included in ARTS 2.0 can be used to complement and expand the search for relevant resistance genes. For example, glycosylation via glycosyl transferases can be used for pro-drug formation and self-protection.^{31,32}

Additional tools utilize a targeted genome mining approach through analyzing genomic data sets for proteins or enzymatic domains that are believed to be a key part of biosynthesis; however, they are not readily detected in the current algorithms for BGC identification. For example, EvoMining³³ utilizes coevolutionary principles for comparative genome mining based on “expansion-and-recruitment events”, gene recruitment associated with signatures of rapid evolution found as enzyme families. This tool has expanded BGC identification and annotation substantially, particularly for those biosynthetic enzymes that are not associated with PKS, NRPS, or hybrid PKS–NRPS systems, and are therefore more difficult to analyze than their more modular counterparts.^{33,34}

Co-occurrence of tandem enzyme domains has been used to identify previously poorly annotated BGCs that are responsible for biosynthesis of oxazolone-containing natural products.³⁵ The aptly named Co-occurrence of Enzymatic Domains (CO-ED) workflow developed by de Rond and colleagues is based on a genome mining approach that focuses on the presence of a series of catalytic domains within a protein that together perform a specific biochemical transformation.³⁵ The workflow was successfully used to interrogate a library of genomes to guide the functional annotation of a new oxazolone synthetase, and subsequently, a suite of new oxazolone natural products was characterized through MS and spectroscopic methods after heterologous expression of the corresponding genes.³⁵

Approach 4: Retrobiosynthesis for Targeted BGC Identification of Known Natural Products. Retrobiosynthetic analysis is the process of determining likely biosynthetic steps based on biosynthetic subunit precursors that comprise the molecule of interest. This analysis can be used to identify if the BGC responsible for a compound of interest is reasonable, particularly when colinear arrangement of genes and enzymatic activity are suspected in the biosynthesis of a given product. This type of modular organization is often seen in Type I PKS, NRPS, and hybrid PKS–NRPS systems. The secondary metabolites that result from these classes of BGCs generally demonstrate colinearity, meaning that the genomic code, enzymatic domains, and resultant chemical structures are closely linked, conferring a degree of predictability.^{36–38} This colinearity can be harnessed to enhance drug discovery efforts. Retrobiosynthetic strategies can predict the specific enzymatic domains that would be responsible for creating a particular structural feature or to match a known structure to the series of enzymatic domains within a BGC. Modular organization of PKS and NRP systems makes them conducive to biotechnological engineering and combinatorial biosynthesis. This, combined with the tight stereospecific control promoted by the biosynthetic enzymes for the architecturally complex natural products,³⁹ makes identification and expression of BGCs particularly appealing.

As demonstrated by our group with palmerolide biosynthesis,⁴⁰ a retrobiosynthetic strategy can be utilized to identify the BGC implicated in the biosynthesis of a specific secondary metabolite out of a diverse metagenome represented by many bacterial genomes. In the case of palmerolide A, key enzymatic

features were used to interrogate the metagenome from environmental samples, and the modular arrangement of the biosynthetic pathway derived from the retrobiosynthetic analysis was used to identify the putative BGC. Identification of the BGC⁴⁰ and host-associated microbial producer⁴¹ now paves the way for drug development efforts through biotechnological means (i.e., through heterologous expression or targeted cultivation efforts). Other examples of BGC identification using similar strategies within genomes of previously characterized polyketide compounds with potent bioactivity include those for calyculin (cytotoxicity),^{42,43} coralopyronins (broad spectrum antibiotic activity),^{44,45} and bryostatins (anticancer and neuroprotective activity).^{46–50} The implications for these strategies cross into the various compound classes and can help propel compounds with pharmaceutical promise through the drug discovery pipeline.

Approach 5: Use of Molecular Networking to Identify and Target New Analogues Arising from the Same or Highly Similar BGCs. Tandem mass spectral data from bacterial cultures or environmental samples can be analyzed in molecular networks via Global Natural Products Social Molecular Networking (GNPS).⁵¹ Useful for library searches for small molecules and peptides, for initial dereplication, and to evaluate the tandem MS data in chemical space, this increasingly robust tool is a powerful companion for drug discovery efforts. Molecular networking can be paired with genomic workflows for analogue molecule identification resulting from BGC expression, whether in the native host or in a heterologous host. Due to the sequential head-to-tail elongation steps that occur in a modular fashion in both modular Type I PKS and NRPS systems, and the diversity introduced by post-translational modifications to the established core sequence within RiPPs, these biosynthetic systems are amenable to combinatorial biosynthetic methods^{37,38} in which molecular networking can be an efficient way of analyzing outcomes.

Molecular networking can be used as a screening tool in novel bacterial cultivation efforts to identify analogues of known natural products as well as to highlight the presence of new metabolites arising from a single BGC. Using m/z differences between interconnected nodes within a cluster, which represent distinct compounds based on a consensus spectrum, structural differences among analogues can be inferred. Alternately, clusters of related ions with no match to known metabolites are indicative of new chemistry. In either case, MS-guided isolation using mass-selective fractionation can be pursued to focus purification strategies on the unknown masses.

Analogues can be formed with heterologous expression of BGCs, as seen with verticilactams,⁵² as well as after deletion or alteration of enzymatic domains within BGCs and subsequent expression, as seen with the BGCs for complestatin and lobophorin.^{53,54} Therefore, after synthetic biology experiments, a molecular network can be used to visualize the biocombinatorial chemical space through uploading the tandem mass spectral data of the metabolites produced by the wild type producer and those that arise from the synthetic biology experiments. A direct comparison can be performed that includes confirmation of contribution to nodes that represent the compound(s) of interest and an evaluation of new nodes that may appear within a compound cluster, indicating new analogues. The MS² fingerprints for nodes representing these additional products can assist in structure elucidation and evaluation of the underlying mechanisms for their biosynthesis. A similar strategy was used following the expression of the

alterchromide BGC⁵⁵ and the cosmomycin BGC⁵⁶ to identify previously undescribed analogues. More recently, molecular networking aided in identification of the production of several new herbicidin analogues following overexpression of the herbicidin BGC⁵⁷ and in a new acylhomoserine lactone (AHL) after expression of an AHL synthase.⁵⁸

Approach 6: Use of Enzymatic Domains within BGCs to Identify Key Structural Features of Unknown Products That Can Be Paired with Analytical Tools. Following annotation of enzymatic domains within a BGC, the presence of a number of domains can be used to identify a previously unknown product or feature within a product, as some metabolomic signatures on MS can be paired with functional enzymatic annotations within BGCs. For example, if a halogenase is present in a BGC, a halogenation signature on MS could be used for the isolation of a halogenated natural product. In a similar manner, the metabolomic signatures for sulfate, phosphate, and carbamate groups can be associated with enzymatic domains such as sulfatases, phosphatases, and carbamoyl transferases. These strategies have potential implications for discovery of natural products and may also play a role in linking an orphan BGC (BGC with no known product) within a bacterial genome to a previously characterized compound containing a specific functional group or groups.

Harnessing the ability to identify isotopic patterns using NMR and MS, isotopically labeled precursors as informed by BGCs, can be used for natural product discovery. In the case of the orfamides, the cultures of *Pseudomonas fluorescens* Pf-5 were fed isotopically labeled amino acids that were selected based upon adenylation domain specificity from the genomic information on an orphan gene cluster. Isotope-guided fractionation using NMR (in parallel with bioassay-guided fractionation) was utilized, and the structure of orfamide A was determined through NMR experiments, GC-MS, and Marfey's analysis.⁵⁹ Building upon the genomisotopic approach, Gerwick and colleagues later enriched the media of cyanobacterial cultures with ¹⁵N-nitrate and performed repeated MALDI experiments on single-filaments of *Moorena producens* JHB that allowed for the identification and subsequent isolation of a new natural product, cryptomaldamide, through an MS-guided fractionation approach.⁶⁰ Full characterization was performed through spectroscopic methods, and the compound's structure was linked to a putative BGC based on genomic analysis. The 28.7 kbp BGC for cryptomaldamide was subsequently heterologously expressed in a genetically tractable host, *Anabaena* PCC, giving further significance to this method of natural product discovery.⁶¹ Recently developed by Lington and colleagues, the IsoAnalyst platform uses isotopic labeling of biosynthetic precursors in parallel feeding experiments paired with MS to link BGCs to their natural products.⁶² The platform utilizes biosynthetic relatedness based on the isotopic patterns rather than deriving structural information on fragments from the tandem mass spectral data. Validated with erythromycin and its analogues, IsoAnalyst was also used to discover a new lobosamide analogue and a new desferrioxamine compound from *Micromonospora* sp.⁶²

Approach 7: Harnessing Paired Genome–Metabolite Data Sets and Tools for Natural Product Discovery. Tools to link BGCs and MS spectra have been developed, in particular, for NRPs. Released by Behsaz and colleagues, NRPminer⁶³ pairs tandem mass spectral data with NRPS BGCs and builds upon previously developed tools, such as NRP2 Path⁶⁴ and NRPquest.⁶⁵ Through a series of steps which integrate

antiSMASH BGC identification from a sequenced genome,¹⁵ GNPS molecular networking of the associated sample,⁵¹ and VarQuest⁶⁶ searches, a list of potential enzymatic assembly lines is populated, filtered, overlaid with potential modifications, and then used to predict possible backbone structures of NRPs. These predicted structures are used to search the mass spectral data for matches that are scored based upon similarity. NRPminer is different from other tools for tandem MS and NRPS BGC pairing as it builds upon the principles of collinearity, allows for broad adenylation domain specificity (including duplication of open reading frames), and is flexible with respect to diverse post-assembly modifications.

Recently, another resource for pairing genomic and metabolomic data sets was released. The Paired Omics Data Platform (PoDP)⁶⁷ is a community-curated platform that links genomic or metagenomic data, metabolomic data, and metadata regarding experimental details on culture, extraction, and instrumentation methods. The purpose of the platform is not to host the big data, but rather link the data that are deposited in various public repositories (many of which have been described above) in order to promote easy access to these carefully curated paired data sets for large computationally driven projects or for smaller scale individual analysis. This tool expands upon the efforts put forth from other teams who have developed concepts designed to link omics databases, including peptidogenomics,⁶⁸ metabologenomics,⁶⁹ and MetaMiner.⁷⁰

■ CONSIDERATIONS AND CHALLENGES

In principle, there are no specific limitations to broad adoption of the approaches and technologies introduced here. Interdisciplinary training across biological and chemical sciences is essential, as are strong computational skills. Likewise, the value of cross-disciplinary collaboration can add paramount value to these studies. However, there are a number of considerations to the selection of an approach including the type of genomic data available and the research objective. Many of the tools and strategies discussed above are amenable to input from various sequence types, including whole genomes, partial genomes, metagenomic assemblies, and metagenome-assembled genomes or single amplified genomes. When considering “big data” and integrating different data types, the source, type, and completeness must be considered in any analyses. Completeness can be problematic in cases of phylogenetic novelty that can influence annotation accuracy and upon analysis of host-associated microbes which may have undergone genomic streamlining. Another barrier to analysis occurs during genome assembly, in which repetitive modules that are often seen in biosynthetic gene clusters can make assembling the sequences challenging. Long-read technologies and specialized assembly pipelines can help overcome this obstacle.⁴¹

Transcriptional regulation of cryptic BGCs presents a challenge to linking sequence to product and is a currently active area of research.^{71–73} Identification of an interesting BGC does not necessarily indicate that the cluster is translated and the product biosynthesized under laboratory culture conditions. At times, unsilencing of cryptic BGCs can be promoted through the one strain—many compounds (OSMAC) approach⁷⁴ or coculture experiments; however, at other times, this is an issue best solved at the genome level through genetic engineering of promoters to control expression in addition to screening at the levels of gene and protein expression as well.

As mentioned in brief above, some BGCs, such as terpene synthases and Type II PKSs, are inherently more challenging to

link to their products due to a lack of collinearity which limits structural prediction. Likewise, nascent understanding of enzymatic subtypes that catalyze specific reactions during biosynthesis limit retrobiosynthetic predictions.

Another hurdle to drug development directly from microbial sources is that cultivation efforts are not always successful, or if isolated in pure culture, growth rates can be suboptimal for scale-up. Along the same lines, heterologous host suitability is an additional consideration. Finding a genetically tractable host can be difficult—particularly for novel lineages. The repertoire of heterologous hosts is dominated by *Streptomyces* strains, although is expanding and currently includes strains of *E. coli*, *Saccharomonospora* sp., *Salinospora* sp., *Pseudoaltermonas* sp., *Anabaena* sp., *Synechococcus* sp., among others.⁷⁵

Lastly, there are also analytical challenges for compound isolation and structure elucidation. For example, low natural abundance chemical analogues identified in a molecular network may preclude subsequent characterization of the proposed analogue.

■ PERSPECTIVES AND POSSIBLE RESEARCH DIRECTIONS

The rise of genomic-based workflows for microbial natural product drug discovery is advancing the field. Genomic approaches for prioritization of bacteria enriched with biosynthetic pathways and deprioritization of BGCs known to produce previously identified compounds can help overcome the hurdle of high rediscovery rates of natural products. Taxonomy, phylogenetics, and the use of coevolutionary principles can aid in prioritization of BGCs. Additionally, in order to address orphan gene clusters or compounds that have not yet been linked to BGCs, retrobiosynthetic principles can be applied. Analytical metabolomic tools remain a mainstay in the natural product drug discovery workflows. Molecular networking is proving to be a powerful tool in identification of analogues produced by wild-type bacteria as well as from those engineered to express BGCs of high interest. The linking of paired genomic and metabolomic data sets will be conducive to large-scale and small-scale comparative and integrative analyses as natural product drug discovery efforts continue.

The field of natural product drug discovery continues to uncover novel molecules. The synergy between genomic and metabolomic approaches realized over the past decade and many of the genomic tools that have been developed have served to set the stage for a new phase of discovery. The creation of community-curated repositories for large-scale natural product data is a powerful and unique contribution to drug discovery that will continue to promote scientific advancement. As genome sequencing continues to become more accessible and more affordable, large-scale sequencing efforts will expand. With this expansion comes opportunity to pair analytical techniques for natural product discovery with genome-based approaches. Many of the approaches are currently microbially based; however, there is need to not only harness the current approaches with prokaryotes but also to extend into eukaryotic systems.

One of the primary bottlenecks for drug development of promising natural products is the issue of supply. The convergence of bacterial genomics, specifically biosynthetic gene clusters, in the drug discovery pipeline allows this issue to be addressed by cultivation or heterologous expression. Barriers beyond limited compound supply include high rediscovery rates and potential ecological impacts of large sample collections.

These hurdles can be circumnavigated and the deleterious effect ameliorated by use of these genomic approaches to drug discovery.

AUTHOR INFORMATION

Corresponding Authors

Nicole E. Avalon — Department of Chemistry, University of South Florida, Tampa, Florida 33620, United States; orcid.org/0000-0003-3588-892X; Email: navalon@ucsf.edu

Alison E. Murray — Division of Earth and Ecosystem Sciences, Desert Research Institute, Reno, Nevada 89512, United States; Email: Alison.Murray@dri.edu

Bill J. Baker — Department of Chemistry, University of South Florida, Tampa, Florida 33620, United States; orcid.org/0000-0003-3033-5779; Email: bjbaker@usf.edu

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.analchem.2c02245>

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported in part by NIH award CA205932 (to A.E.M. and B.J.B.). The development of our genomics-based workflow was informed by significant interactions with Patrick S. G. Chain, Chien-Chi Lo, Hajnalka E. Daligault and Karen W. Davenport from the Los Alamos National Laboratory, Los Alamos, New Mexico, United States.

REFERENCES

- Ricke, D. O.; Wang, S.; Cai, R.; Cohen, D. *Curr. Opin. Chem. Biol.* **2006**, *10*, 303–308.
- Xia, X. *Curr. Top. Med. Chem.* **2017**, *17*, 1709–1726.
- Clardy, J.; Walsh, C. *Nature* **2004**, *432*, 829–37.
- Newman, D. J.; Cragg, G. M. *J. Nat. Prod.* **2020**, *83*, 770–803.
- Louwen, J. J. R.; van der Hooft, J. J. J. *mSystems* **2021**, *6*, e0072621–e0072621.
- Chevrette, M. G.; Gavrilidou, A.; Mantri, S.; Selem-Mojica, N.; Ziemert, N.; Barona-Gómez, F. *Nat. Prod. Rep.* **2021**, *38*, 2024–2040.
- van Santen, J. A.; Kautsar, S. A.; Medema, M. H.; Linington, R. G. *Nat. Prod. Rep.* **2021**, *38*, 264–278.
- Scott, T. A.; Piel, J. *Nat. Rev. Chem.* **2019**, *3*, 404–425.
- Schmitt, I.; Lumbusch, H. T. *PLoS One* **2009**, *4*, e4437.
- Ravenhall, M.; Škunca, N.; Lassalle, F.; Dessimoz, C. *PLOS Comp. Biol.* **2015**, *11*, e1004095.
- Chang, H.-Y.; Colby, S. M.; Du, X.; Gomez, J. D.; Helf, M. J.; Kechris, K.; Kirkpatrick, C. R.; Li, S.; Patti, G. J.; Renslow, R. S.; Subramaniam, S.; Verma, M.; Xia, J.; Young, J. D. *Anal. Chem.* **2021**, *93*, 1912–1923.
- Adamek, M.; Alanjary, M.; Ziemert, N. *Nat. Prod. Rep.* **2019**, *36*, 1295–1312.
- Albarano, L.; Esposito, R.; Ruocco, N.; Costantini, M. *Mar. Drugs* **2020**, *18*, 199.
- Agarwala, R.; Barrett, T.; Beck, J.; Benson, D. A.; Bollin, C.; Bolton, E.; Bourexis, D.; Brister, J. R.; Bryant, S. H.; Canese, K.; Cavanaugh, M.; Charowhas, C.; Clark, K.; Dondoshansky, I.; Feolo, M.; Fitzpatrick, L.; Funk, K.; Geer, L. Y.; Gorelenkov, V.; Graeff, A.; Hlavina, W.; Holmes, B.; Johnson, M.; Kattman, B.; Khotomlianski, V.; Kimchi, A.; Kimelman, M.; Kimura, M.; Kitts, P.; Klimke, W.; Kotliarov, A.; Krasnov, S.; Kuznetsov, A.; Landrum, M. J.; Landsman, D.; Lathrop, S.; Lee, J. M.; Leubsdorf, C.; Lu, Z.; Madden, T. L.; Marchler-Bauer, A.; Malheiro, A.; Meric, P.; Karsch-Mizrachi, I.; Mnev, A.; Murphy, T.; Orris, R.; Ostell, J.; O'Sullivan, C.; Palanigobu, V.; Panchenko, A. R.; Phan, L.; Pierov, B.; Pruitt, K. D.; Rodarmer, K.; Sayers, E. W.; Schneider, V.; Schoch, C. L.; Schuler, G. D.; Sherry, S. T.; Siyan, K.; Soboleva, A.; Sousoff, V.; Starchenko, G.; Tatusova, T. A.; Thibaud-Nissen, F.; Todorov, K.; Trawick, B. W.; Vakarov, D.; Ward, M.; Yaschenko, E.; Zasytkin, A.; Zbic, K. *Nucleic Acids Res.* **2018**, *46*, D8–D13.
- Blin, K.; Shaw, S.; Steinke, K.; Villebro, R.; Ziemert, N.; Lee, S. Y.; Medema, M. H.; Weber, T. *Nucleic Acids Res.* **2019**, *47*, W81–W87.
- Altschul, S. F.; Gish, W.; Miller, W.; Myers, E. W.; Lipman, D. J. *J. Mol. Biol.* **1990**, *215*, 403–410.
- Markowitz, V. M.; Chen, I.-M. A.; Palaniappan, K.; Chu, K.; Szeto, E.; Grechkin, Y.; Ratner, A.; Jacob, B.; Huang, J.; Williams, P.; Huntemann, M.; Anderson, I.; Mavromatis, K.; Ivanova, N. N.; Kyrpides, N. C. *Nucleic Acids Res.* **2012**, *40*, D115–D122.
- Navarro-Muñoz, J. C.; Selem-Mojica, N.; Mallowney, M. W.; Kautsar, S. A.; Tryon, J. H.; Parkinson, E. I.; De Los Santos, E. L. C.; Yeong, M.; Cruz-Morales, P.; Abubucker, S.; Roeters, A.; Lokhorst, W.; Fernandez-Guerra, A.; Cappelini, L. T. D.; Goering, A. W.; Thomson, R. J.; Metcalf, W. W.; Kelleher, N. L.; Barona-Gomez, F.; Medema, M. H. *Nature Chem. Biol.* **2020**, *16*, 60–68.
- Kautsar, S. A.; Blin, K.; Shaw, S.; Navarro-Muñoz, J. C.; Terlow, B. R.; van der Hooft, J. J. J.; van Santen, J. A.; Tracanna, V.; Suarez Duran, H. G.; Pascal Andreu, V.; et al. *Nucleic Acids Res.* **2020**, *48*, D454–D458.
- van Santen, J. A.; Jacob, G.; Singh, A. L.; Aniebok, V.; Balunas, M. J.; Bunsko, D.; Neto, F. C.; Castaño-Espriu, L.; Chang, C.; Clark, T. N.; et al. *ACS Cent. Sci.* **2019**, *5*, 1824–1833.
- Palaniappan, K.; Chen, I.-M. A.; Chu, K.; Ratner, A.; Seshadri, R.; Kyrpides, N. C.; Ivanova, N. N.; Mouncey, N. J. *Nucleic Acids Res.* **2020**, *48*, D422–D430.
- Nayfach, S.; Roux, S.; Seshadri, R.; Udway, D.; Varghese, N.; Schulz, F.; Wu, D.; Paez-Espino, D.; Chen, I. M.; Huntemann, M.; et al. *Nat. Biotechnol.* **2021**, *39*, 499–509.
- Murray, A. E.; Avalon, N. E.; Bishop, L.; Davenport, K. W.; Delage, E.; Dichosa, A. E. K.; Eveillard, D.; Higham, M. L.; Kokkaliari, S.; Lo, C.-C.; Riesenfeld, C. S.; Young, R. M.; Chain, P. S. G.; Baker, B. J. *Mar. Drugs* **2020**, *18*, 298.
- Leão, T.; Wang, M.; Moss, N.; da Silva, R.; Sanders, J.; Nurk, S.; Gurevich, A.; Humphrey, G.; Reher, R.; Zhu, Q.; et al. *Mar. Drugs* **2021**, *19*, 20.
- Soldatou, S.; Eldjárn, G. H.; Ramsay, A.; van der Hooft, J. J. J.; Hughes, A. H.; Rogers, S.; Duncan, K. R. *Mar. Drugs* **2021**, *19*, 103.
- Handayani, I.; Saad, H.; Ratnakomala, S.; Lisdiyanti, P.; Kusharyoto, W.; Krause, J.; Kulik, A.; Wohlleben, W.; Aziz, S.; Gross, H.; Gavrilidou, A.; Ziemert, N.; Mast, Y. *Mar. Drugs* **2021**, *19*, 316.
- Ziemert, N.; Podell, S.; Penn, K.; Badger, J. H.; Allen, E.; Jensen, P. R. *PLoS One* **2012**, *7*, e34064.
- Alanjary, M.; Steinke, K.; Ziemert, N. *Nucleic Acids Res.* **2019**, *47*, W276–W282.
- Mungan, M. D.; Alanjary, M.; Blin, K.; Weber, T.; Medema, M. H.; Ziemert, N. *Nucleic Acids Res.* **2020**, *48*, W546–W552.
- Almabruk, K. H.; Dinh, L. K.; Philmus, B. *ACS Chem. Biol.* **2018**, *13*, 1426–1437.
- Quirós, L. M.; Aguirrezabalaga, I.; Olano, C.; Méndez, C.; Salas, J. A. *Mol. Microbiol.* **1998**, *28*, 1177–1185.
- Wencewicz, T. A. *J. Mol. Biol.* **2019**, *431*, 3370–3399.
- Sélem-Mojica, N.; Aguilar, C.; Gutiérrez-García, K.; Martínez-Guerrero, C. E.; Barona-Gómez, F. *Microb. Genom.* **2019**, *5*, e000260.
- Cruz-Morales, P.; Kopp, J. F.; Martínez-Guerrero, C. E.; Yáñez-Guerra, L. A.; Sélem-Mojica, N.; Ramos-Aboites, H. E.; Feldmann, J.; Barona-Gómez, F. *Genom. Biol. Evol.* **2016**, *8*, 1906–1916.
- de Rond, T.; Asay, J. E.; Moore, B. S. *Nature Chem. Biol.* **2021**, *17*, 794–799.
- Helfrich, E. J.; Piel, J. *Nat. Prod.* **2016**, *33*, 231–316.
- Cane, D. E.; Walsh, C. T.; Khosla, C. *Science* **1998**, *282*, 63–8.

- (38) Sardar, D.; Schmidt, E. W. *Curr. Opinion Chem. Biol.* **2016**, *31*, 15–21.
- (39) Montaser, R.; Luesch, H. *Future Med. Chem.* **2011**, *3*, 1475–1489.
- (40) Avalon, N. E.; Murray, A. E.; Daligault, H. E.; Lo, C.-C.; Davenport, K. W.; Dichosa, A. E. K.; Chain, P. S. G.; Baker, B. J. *Front. Chem.* **2021**, *9*, 802574.
- (41) Murray, A. E.; Lo, C.-C.; Daligault, H. E.; Avalon, N. E.; Read, R. W.; Davenport, K. W.; Higham, M. L.; Kunde, Y.; Dichosa, A. E. K.; Baker, B. J.; Chain, P. S. G. *mSphere* **2021**, *6*, e0075921.
- (42) Suganuma, M.; Fujiki, H.; Furuya-Suguri, H.; Yoshizawa, S.; Yasumoto, S.; Kato, Y.; Fusetani, N.; Sugimura, T. *Cancer Res.* **1990**, *50*, 3521–3525.
- (43) Wakimoto, T.; Egami, Y.; Nakashima, Y.; Wakimoto, Y.; Mori, T.; Awakawa, T.; Ito, T.; Kenmoku, H.; Asakawa, Y.; Piel, J.; Abe, I. *Nature Chem. Biol.* **2014**, *10*, 648–655.
- (44) Jansen, R.; Höfle, G.; Irschik, H.; Reichenbach, H. *Liebigs Ann. Chem.* **1985**, *1985*, 822–836.
- (45) Erol, Ö.; Schäberle, T. F.; Schmitz, A.; Rachid, S.; Gurgui, C.; El Omari, M.; Lohr, F.; Kehraus, S.; Piel, J.; Müller, R.; König, G. M. *ChemBioChem* **2010**, *11*, 1253–1265.
- (46) Sudek, S.; Lopanik, N. B.; Waggoner, L. E.; Hildebrand, M.; Anderson, C.; Liu, H.; Patel, A.; Sherman, D. H.; Haygood, M. G. *J. Nat. Prod.* **2007**, *70*, 67–74.
- (47) Buchholz, T. J.; Rath, C. M.; Lopanik, N. B.; Gardner, N. P.; Håkansson, K.; Sherman, D. H. *Chem. Biol.* **2010**, *17*, 1092–1100.
- (48) Banerjee, S.; Wang, Z.; Mohammad, M.; Sarkar, F. H.; Mohammad, R. M. *J. Nat. Prod.* **2008**, *71*, 492–496.
- (49) Nelson, T. J.; Alkon, D. L. *Trend. Biochem. Sci.* **2009**, *34*, 136–145.
- (50) Sun, M.-K.; Alkon, D. L. *Eur. J. Pharmacol.* **2005**, *512*, 43–51.
- (51) Wang, M. X.; Carver, J. J.; Phelan, V. V.; Sanchez, L. M.; Garg, N.; Peng, Y.; Nguyen, D. D.; Watrous, J.; Kaponov, C. A.; Luzzatto-Knaan, T.; et al. *Nat. Biotechnol.* **2016**, *34*, 828–837.
- (52) Nogawa, T.; Terai, A.; Amagai, K.; Hashimoto, J.; Futamura, Y.; Okano, A.; Fujie, M.; Satoh, N.; Ikeda, H.; Shin-ya, K.; Osada, H.; Takahashi, S. *J. Nat. Prod.* **2020**, *83*, 3598–3605.
- (53) Park, O.-K.; Choi, H.-Y.; Kim, G.-W.; Kim, W.-G. *ChemBioChem* **2016**, *17*, 1725–1731.
- (54) Tan, B.; Chen, S.; Zhang, Q.; Chen, Y.; Zhu, Y.; Khan, I.; Zhang, W.; Zhang, C. *Org. Lett.* **2020**, *22*, 1062–1066.
- (55) Ross, A. C.; Gulland, L. E. S.; Dorrestein, P. C.; Moore, B. S. *ACS Synth. Biol.* **2015**, *4*, 414–420.
- (56) Larson, C. B.; Crüsemann, M.; Moore, B. S. *J. Nat. Prod.* **2017**, *80*, 1200–1204.
- (57) Shi, Y.; Gu, R.; Li, Y.; Wang, X.; Ren, W.; Li, X.; Wang, L.; Xie, Y.; Hong, B. *Microb. Cell Factor.* **2019**, *18*, 175.
- (58) Albataineh, H.; Duke, M.; Misra, S. K.; Sharp, J. S.; Stevens, D. C. *Sci. Rep.* **2021**, *11*, 3018.
- (59) Gross, H.; Stockwell, V. O.; Henkels, M. D.; Nowak-Thompson, B.; Loper, J. E.; Gerwick, W. H. *Chem. Biol.* **2007**, *14*, 53–63.
- (60) Kinnel, R. B.; Esquenazi, E.; Leao, T.; Moss, N.; Mevers, E.; Pereira, A. R.; Monroe, E. A.; Korobeynikov, A.; Murray, T. F.; Sherman, D.; Gerwick, L.; Dorrestein, P. C.; Gerwick, W. H. *J. Nat. Prod.* **2017**, *80*, 1514–1521.
- (61) Taton, A.; Ecker, A.; Diaz, B.; Moss, N. A.; Anderson, B.; Reher, R.; Leão, T. F.; Simkovsky, R.; Dorrestein, P. C.; Gerwick, L.; Gerwick, W. H.; Golden, J. W. *ACS Synth. Biol.* **2020**, *9*, 3364–3376.
- (62) McCaughey, C. S.; van Santen, J. A.; van der Hooft, J. J. J.; Medema, M. H.; Linington, R. G. *Nature Chem. Biol.* **2022**, *18*, 295–304.
- (63) Behsaz, B.; Bode, E.; Gurevich, A.; Shi, Y.-N.; Grundmann, F.; Acharya, D.; Caraballo-Rodríguez, A. M.; Bouslimani, A.; Panitchpakdi, M.; Linck, A.; Guan, C.; Oh, J.; Dorrestein, P. C.; Bode, H. B.; Pevzner, P. A.; Mohimani, H. *Nature Commun.* **2021**, *12*, 3225.
- (64) Medema, M. H.; Paalvast, Y.; Nguyen, D. D.; Melnik, A.; Dorrestein, P. C.; Takano, E.; Breitling, R. *PLoS Comp. Biol.* **2014**, *10*, e1003822.
- (65) Mohimani, H.; Liu, W.-T.; Kersten, R. D.; Moore, B. S.; Dorrestein, P. C.; Pevzner, P. A. *J. Nat. Prod.* **2014**, *77*, 1902–1909.
- (66) Gurevich, A.; Mikheenko, A.; Shlemov, A.; Korobeynikov, A.; Mohimani, H.; Pevzner, P. A. *Nature Microbiol.* **2018**, *3*, 319–327.
- (67) Schorn, M. A.; Verhoeven, S.; Ridder, L.; Huber, F.; Acharya, D. D.; Aksenov, A. A.; Aleti, G.; Moghaddam, J. A.; Aron, A. T.; Aziz, S.; et al. *Nature Chem. Biol.* **2021**, *17*, 363–368.
- (68) Kersten, R. D.; Yang, Y.-L.; Xu, Y.; Cimermancic, P.; Nam, S.-J.; Fenical, W.; Fischbach, M. A.; Moore, B. S.; Dorrestein, P. C. *Nature Chem. Biol.* **2011**, *7*, 794–802.
- (69) Goering, A. W.; McClure, R. A.; Doroghazi, J. R.; Albright, J. C.; Haverland, N. A.; Zhang, Y.; Ju, K.-S.; Thomson, R. J.; Metcalf, W. W.; Kelleher, N. L. *ACS Cent. Sci.* **2016**, *2*, 99–108.
- (70) Cao, L.; Gurevich, A.; Alexander, K. L.; Naman, C. B.; Leao, T.; Glukhov, E.; Luzzatto-Knaan, T.; Vargas, F.; Quinn, R.; Bouslimani, A.; Nothias, L. F.; Singh, N. K.; Sanders, J. G.; Benitez, R. A. S.; Thompson, L. R.; Hamid, M.-N.; Morton, J. T.; Mikheenko, A.; Shlemov, A.; Korobeynikov, A.; Friedberg, I.; Knight, R.; Venkateswaran, K.; Gerwick, W. H.; Gerwick, L.; Dorrestein, P. C.; Pevzner, P. A.; Mohimani, H. *Cell Systems* **2019**, *9*, 600–608.
- (71) Covington, B. C.; Xu, F.; Seyedsayamdost, M. R. *Annu. Rev. Biochem.* **2021**, *90*, 763–788.
- (72) Luo, Y.; Huang, H.; Liang, J.; Wang, M.; Lu, L.; Shao, Z.; Cobb, R. E.; Zhao, H. *Nature Commun.* **2013**, *4*, 2894.
- (73) Yushchuk, O.; Ostash, I.; Mösker, E.; Vlasiuk, I.; Deneka, M.; Rückert, C.; Busche, T.; Fedorenko, V.; Kalinowski, J.; Süßmuth, R. D.; Ostash, B. *Sci. Rep.* **2021**, *11*, 3507.
- (74) Bode, H. B.; Bethe, B.; Hofs, R.; Zecek, A. *Chembiochem* **2002**, *3*, 619–627.
- (75) Wang, G.; Zhao, Z.; Ke, J.; Engel, Y.; Shi, Y.-M.; Robinson, D.; Bingol, K.; Zhang, Z.; Bowen, B.; Louie, K.; et al. *Nature Microbiol.* **2019**, *4*, 2498–2510.